<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730730</url>
  </required_header>
  <id_info>
    <org_study_id>IP084</org_study_id>
    <secondary_id>IDE G070114</secondary_id>
    <nct_id>NCT00730730</nct_id>
  </id_info>
  <brief_title>The Complete® Self-Expanding Stent and Stent Delivery System Registry</brief_title>
  <official_title>The Medtronic Complete® Self-Expanding Stent and Stent Delivery System Registry: a Non-randomized Prospective, Multicenter, Consecutive Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show if a new delivery system with a modified stent is safe
      in treating occluded iliac arteries in patients with peripheral vascular disease. The
      modified Complete SE delivery system is hypothesized to assist physicians with more accurate
      stent placement reducing the likelihood of stent 'jumping' seen with the use of many
      self-expanding stent systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is being conducted to collect the 30-day safety data on the stent delivery system
      for all subjects enrolled into the study (with a minimum of 50 subjects enrolled) as well as
      the long-term 9-month safety and efficacy data on all subjects enrolled (with a minimum of 10
      subjects enrolled into the study having the 120mm length stent implanted).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse events (MAE) defined as any death, target limb loss or clinically-driven Target Lesion Revascularization (TLR)/Target Vessel Revascularization (TVR) with percutaneous transluminal angioplasty or aorto-iliac bypass graft) for all subjects enrolled into the registry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Success</measure>
    <time_frame>from after stent placement to prior to hospital discharge (up to 3 days)</time_frame>
    <description>angiographic evidence of &lt; 30 % final residual stenosis of the target lesion after stent placement with no occurrence of a device- related, procedure-related MAE or vascular event (stent thrombosis, major bleeding complications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Limbs With Improvement Using Rutherford Scale to Determine Clinical Success.</measure>
    <time_frame>From baseline up to 30-days</time_frame>
    <description>Improvement of Rutherford scale by ≥ 1 category between pre-procedure (Baseline) and 30-day follow-up-
Category 0: Asymptomatic, no hemodynamically significant occlusive disease;
Category 1: Mild claudication;
Category 2: Moderate claudication;
Category 3: Severe claudication;
Category 4: Ischemic rest pain;
Category 5: Minor tissue loss; non-healing ulcer; focal gangrene with diffuse pedal ischemia;
Category 6: Major tissue loss extending above transmetatarsal level;functional foot no longer salvageable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Limbs With Improvement Using Ankle-brachial Index and Toe Brachial Index to Determine Hemodynamic Success.</measure>
    <time_frame>From baseline up to 30-days</time_frame>
    <description>Improvement in ankle-brachial index (ABI) or toe-brachial index (TBI) &gt; 0.10 over pre-procedure level OR deterioration by ≤ 0.15 from first post-procedure exam OR pulse volume recording (PVR) distal to the target lesion treated maintained at ≥ 5 mm above pre-procedure tracing for those subjects with no pre-procedure ABI/TBI.
An ABI ≥ 0.90 is considered normal.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Complete SE Iliac Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complete SE Iliac Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Complete SE Iliac Stent</intervention_name>
    <description>Iliac stenting</description>
    <arm_group_label>Complete SE Iliac Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Complete SE Iliac Stent</intervention_name>
    <description>Self-expanding stent</description>
    <arm_group_label>Complete SE Iliac Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The lesion(s) is either de-novo or restenotic in nature, located in either the common
             iliac artery or the external iliac artery and is &gt;50% stenosed

          -  Target vessel reference diameter ≥ 4.5 mm and ≤ 9.5 and can accommodate stent
             diameters of 6.0 - 10.0mm

          -  Subject is either asymptomatic with a lesion stenosis ≥70% or symptomatic with a
             lesion stenosis ≥50% with an Ankle Brachial Index (ABI) &lt; 0.90 or Toe Brachial Index
             (TBI) &lt;0.80 or an abnormal Pulse Volume Recording (PVR);

          -  Total lesion length is &lt; 110 mm;

        Exclusion Criteria:

          -  Excessive Peripheral Vascular Disease (PVD), unresolved fresh thrombus or tortuosity
             or a target lesion/vessel that is heavily calcified ;

          -  Tissue loss in the extremity: category 5 or 6 on the Rutherford scale;

          -  Target lesion has a previous stent, or is within a prosthetic vascular bypass graft or
             within 1 cm of a graft anastomosis;

          -  Target lesion is within an aneurysm or associated with an aneurysm in the vessel
             segment proximal or distal to the target lesion;

          -  Lesion requires treatment with a non-standard device associated with Percutaneous
             Transluminal Angioplasty (PTA) prior to stent placement;

          -  Inadequate distal run-off;

          -  Planned interventional procedure or vascular surgery to target vessel within 30 days
             pre- or post-index iliac procedure;

          -  History of bleeding diatheses or coagulopathy or will refuse blood transfusions;

          -  Platelet count &lt;50,000 cells/mm3 or &gt;700,000 cells/mm3, or White Blood Count (WBC)
             &lt;3,000 cells/mm3;

          -  Creatinine &gt;2.0 mg/dl;

          -  Participation in another investigational device or drug study and has not completed
             the primary endpoint(s) follow-up phase of that study at least 30 days prior to
             enrollment in this trial or the subject has previously been enrolled in this Registry;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Molnar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Vascular Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Gray</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital/Columbia Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michigan Vascular Research Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital, Columbia Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>November 11, 2010</results_first_submitted>
  <results_first_submitted_qc>March 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2011</results_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iliac Artery, Peripheral Vascular Disease (PVD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Complete SE Iliac Stent</title>
          <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iliac Stenting</title>
          <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Major Adverse Events (MAE)</title>
        <description>Major adverse events (MAE) defined as any death, target limb loss or clinically-driven Target Lesion Revascularization (TLR)/Target Vessel Revascularization (TVR) with percutaneous transluminal angioplasty or aorto-iliac bypass graft) for all subjects enrolled into the registry</description>
        <time_frame>30 days</time_frame>
        <population>Intent-to-treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Complete SE Iliac Stent</title>
            <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Major Adverse Events (MAE)</title>
          <description>Major adverse events (MAE) defined as any death, target limb loss or clinically-driven Target Lesion Revascularization (TLR)/Target Vessel Revascularization (TVR) with percutaneous transluminal angioplasty or aorto-iliac bypass graft) for all subjects enrolled into the registry</description>
          <population>Intent-to-treat population (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Success</title>
        <description>angiographic evidence of &lt; 30 % final residual stenosis of the target lesion after stent placement with no occurrence of a device- related, procedure-related MAE or vascular event (stent thrombosis, major bleeding complications)</description>
        <time_frame>from after stent placement to prior to hospital discharge (up to 3 days)</time_frame>
        <population>Intent to Treat population(ITT); missing angiographic data for one patient</population>
        <group_list>
          <group group_id="O1">
            <title>Complete SE Iliac Stent</title>
            <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Success</title>
          <description>angiographic evidence of &lt; 30 % final residual stenosis of the target lesion after stent placement with no occurrence of a device- related, procedure-related MAE or vascular event (stent thrombosis, major bleeding complications)</description>
          <population>Intent to Treat population(ITT); missing angiographic data for one patient</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Limbs With Improvement Using Rutherford Scale to Determine Clinical Success.</title>
        <description>Improvement of Rutherford scale by ≥ 1 category between pre-procedure (Baseline) and 30-day follow-up-
Category 0: Asymptomatic, no hemodynamically significant occlusive disease;
Category 1: Mild claudication;
Category 2: Moderate claudication;
Category 3: Severe claudication;
Category 4: Ischemic rest pain;
Category 5: Minor tissue loss; non-healing ulcer; focal gangrene with diffuse pedal ischemia;
Category 6: Major tissue loss extending above transmetatarsal level;functional foot no longer salvageable</description>
        <time_frame>From baseline up to 30-days</time_frame>
        <population>Analysis calculated using number of evaluable limbs with Rutherford results; data missing for two limbs</population>
        <group_list>
          <group group_id="O1">
            <title>Complete SE Iliac Stent</title>
            <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Limbs With Improvement Using Rutherford Scale to Determine Clinical Success.</title>
          <description>Improvement of Rutherford scale by ≥ 1 category between pre-procedure (Baseline) and 30-day follow-up-
Category 0: Asymptomatic, no hemodynamically significant occlusive disease;
Category 1: Mild claudication;
Category 2: Moderate claudication;
Category 3: Severe claudication;
Category 4: Ischemic rest pain;
Category 5: Minor tissue loss; non-healing ulcer; focal gangrene with diffuse pedal ischemia;
Category 6: Major tissue loss extending above transmetatarsal level;functional foot no longer salvageable</description>
          <population>Analysis calculated using number of evaluable limbs with Rutherford results; data missing for two limbs</population>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Limbs With Improvement Using Ankle-brachial Index and Toe Brachial Index to Determine Hemodynamic Success.</title>
        <description>Improvement in ankle-brachial index (ABI) or toe-brachial index (TBI) &gt; 0.10 over pre-procedure level OR deterioration by ≤ 0.15 from first post-procedure exam OR pulse volume recording (PVR) distal to the target lesion treated maintained at ≥ 5 mm above pre-procedure tracing for those subjects with no pre-procedure ABI/TBI.
An ABI ≥ 0.90 is considered normal.</description>
        <time_frame>From baseline up to 30-days</time_frame>
        <population>Evaluable Ankle-brachial Index (ABI)/Toe brachial Index (TBI)result: missing data for 1 limb</population>
        <group_list>
          <group group_id="O1">
            <title>Complete SE Iliac Stent</title>
            <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Limbs With Improvement Using Ankle-brachial Index and Toe Brachial Index to Determine Hemodynamic Success.</title>
          <description>Improvement in ankle-brachial index (ABI) or toe-brachial index (TBI) &gt; 0.10 over pre-procedure level OR deterioration by ≤ 0.15 from first post-procedure exam OR pulse volume recording (PVR) distal to the target lesion treated maintained at ≥ 5 mm above pre-procedure tracing for those subjects with no pre-procedure ABI/TBI.
An ABI ≥ 0.90 is considered normal.</description>
          <population>Evaluable Ankle-brachial Index (ABI)/Toe brachial Index (TBI)result: missing data for 1 limb</population>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="93.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Iliac Stenting</title>
          <description>Iliac stenting (Complete® Self-Expanding Stent) for the treatment of de novo and restenotic lesions in iliac arteries in subjects with peripheral vascular disease (PVD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>NSTEMI - Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Shock Liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pseudoaneurysm Left Femoral Artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dissection - Target Vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Right Lower Extremity Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Right Toe Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator/Institution agree to submit to Sponsor copies of any proposed publication/public presentation (“Proposed Publication”) at least sixty (60) calendar days in advance of dissemination. Sponsor will review/comment within thirty (30) calendar days after receipt thereof. If Sponsor objects to dissemination of any part of the Proposed Publication, Investigator, and Institution shall refrain from disseminating or presenting such Proposed Publication until Sponsor is satisfied.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arslan Malik - Senior Clinical Research Manager</name_or_title>
      <organization>Medtronic Aortic and Peripheral Vascular</organization>
      <phone>(707) 541-3256</phone>
      <email>arslan.malik@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

